Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMG 007

Next Previous
X
Search
Drug Profile

IMG 007

Alternative Names: HMPL-A28; IMG-007

Latest Information Update: 13 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HUTCHMED
  • Developer Inmagene
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action OX40 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I/II Alopecia areata; Atopic dermatitis

Most Recent Events

  • 07 May 2024 Inmagene completes enrolment in its phase I/II trial in Alopecia areata in USA, Canada (IV) (NCT06060977)
  • 06 May 2024 Efficacy and adverse event data from a phase Ib/IIa trial in Atopic dermatitis released by Inmagene
  • 26 Apr 2024 Inmagene Biopharmaceuticals terminates a phase I/II trial in Atopic dermatitis (Treatment-experienced) in Canada (IV) as the sponsor believes that results from Cohort 1 will provide reliable information for further development decision (NCT05984784)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top